We performed an open-label, single-arm phase II clinical trial to investigate the efficacy and safety of afatinib alone and in combination with vinorelbine following disease progression in patients with HER2-positive IBC. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.